Recent Updates
Recently added Catalysts

Advanced Gastroesophageal Adenocarcinoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$3.8Buniverse median $1.20B
Allocated capital$767M$3.8B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank170/299crowding rank 181

Advanced Gastroesophageal Adenocarcinoma is uncontested. Arcus Biosciences (RCUS) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Zimberelimab in phase 3.

There is no public comparable to price it against. RCUS spreads its $3.8B market cap across 5 indications, so $767M of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$767M of allocated capital sits in Advanced Gastroesophageal Adenocarcinoma, ranking it 170th of 299 indications by the money committed to it.

Companies developing drugs for Advanced Gastroesophageal Adenocarcinoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
RCUSArcus BiosciencesZimberelimabPhase 32$3.8BNo5 14 Nov 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Advanced Gastroesophageal Adenocarcinoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Advanced Gastroesophageal Adenocarcinoma has one competitor and a median of $3.8B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Pancreatic Ductal Adenocarcinoma1 company · $768M · median $3.8BUncontestedMetastatic Head and Neck Squamous Cell Carcinoma1 company · $772M · median $1.5BUncontestedGlioma1 company · $792M · median $2.4BUncontestedAdvanced EGFR Mutant Non-Small Cell Lung Cancer1 company · $794M · median $794MUncontestedCancer Pain1 company · $798M · median $4.0BUncontestedNon-Muscle Invasive Bladder Cancer (NMIBC)1 company · $723M · median $8.7BUncontestedRefractory Non-Hodgkin's Lymphoma1 company · $723M · median $8.7BUncontestedHPV-Related Carcinoma1 company · $723M · median $8.7BUncontested

Advanced Gastroesophageal Adenocarcinoma pipeline questions

Which biotech companies are developing drugs for Advanced Gastroesophageal Adenocarcinoma?

Arcus Biosciences (RCUS, Zimberelimab, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Advanced Gastroesophageal Adenocarcinoma.

How advanced is the Advanced Gastroesophageal Adenocarcinoma pipeline?

Of the 1 clinical-stage programme in Advanced Gastroesophageal Adenocarcinoma, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Advanced Gastroesophageal Adenocarcinoma?

No. RCUS is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Advanced Gastroesophageal Adenocarcinoma, which is why the indication is classified as uncontested.

When is the next Advanced Gastroesophageal Adenocarcinoma catalyst?

The next dated catalyst in Advanced Gastroesophageal Adenocarcinoma is RCUS on 14 Nov 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map